Lumexa Imaging Holdings, Inc.
Lumexa Imaging Holdings, Inc. is a U.S. diagnostic imaging services company that owns and operates outpatient imaging centers across multiple states. Lumexa Imaging provides a broad range of medical imaging and screening services, including MRI, CT, PET, X-ray, ultrasound, and mammography, supporting the diagnosis and monitoring of a wide variety of conditions. The company also offers professional interpretation services for imaging studies through its radiology-focused operations and teleradiology platform. Its business is organized around outpatient imaging centers and professional services, allowing it to serve patients, referring physicians, health systems, and other care providers. Based in Raleigh, North Carolina, Lumexa Imaging plays a meaningful role in expanding access to noninvasive diagnostic services within the U.S. health care market.
$10.78
+$0.00 (+0.00%)
EOD Oct 16, 2026
Operating margin is thin at 2.61%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 7.8%, steady but not accelerating. Free cash flow declined 149% despite revenue growth, conversion is weakening.
Free cash flow declined 149% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -$6M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.04B
▲ +7.8% YoY
Net Income (TTM)
-$28M
▲ +49.9% YoY
Op. Margin
1.38%
▲ +4.3pp YoY
ROIC
1.40%
▲ +2.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$31M
▼ -149.4% YoY
Op. Cash Flow (TTM)
$65M
▼ -21.9% YoY
Net Debt
$904M
Cash & Equiv.
$59M
Continue Research
Is Lumexa Imaging Holdings (LMRI) overvalued?
Lumexa Imaging Holdings (LMRI) trades above a two-stage DCF intrinsic value of about $7.01 per share, so at $10.78 the stock looks overvalued (35.0% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Lumexa Imaging Holdings scores 42/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Lumexa Imaging Holdings's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $7.01 per share for LMRI, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $5.26. At today's $10.78, that puts the stock about 35.0% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Lumexa Imaging Holdings a high-quality business?+
Lumexa Imaging Holdings scores 42 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 1.4% operating margin and a 1.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Lumexa Imaging Holdings a good stock to buy right now?+
That depends on valuation and quality together, not either alone. LMRI currently trades above its estimated intrinsic value and scores 42/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Medical Devices
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.